| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 1.7MM | +18% |
| Operating Income | 512.7K | +61% |
| Operating Expenses | 1.1MM | +5% |
| Net Income | 345.6K | +28% |
| G&A | 335.2K | +10% |
| Interest Expense | 1.1K | -0% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
MIDLAND, TX, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Mexco Energy Corporation (NYSE American: MXC) today reported net income of $345,610, or $0.16 per diluted share, for the Company’s third quarter of fiscal 2024, an increase of 28% compared to $269,433, or $0.12 per diluted share, for the second quarter of fiscal 2024. Operating revenues in the third quarter of fiscal 2024 were $1,656,443. The average sales price of oil and natural gas for the three months ending December 31, 2023 was $78.65 per barr
Financial Performance for the First Six Months of Fiscal 2024
MIDLAND, TX, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Mexco Energy Corporation (NYSE American: MXC) today reported net income for the six months ending September 30, 2023 was $735,047, or $0.34 per diluted share, a decrease of 71% compared to the same six-month period of fiscal 2023. Operating revenues in the first six months of fiscal 2024 decreased 34% to $3,155,029. This decrease resulted from a 26% decrease in the average sales price of oil and a 68% decrease in the average sales price of natural g
MIDLAND, TX, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Mexco Energy Corporation (NYSE American: MXC) today reported net income of $465,614, or $0.21 per diluted share, for the quarter ending June 30, 2023, compared to $1,298,672 or $0.59 per diluted share, for the comparable quarter ending June 30, 2022. Operating revenues in the first quarter of fiscal 2024 were $1,748,419, a decrease of 29% from the first quarter of fiscal 2023. This was due to a 33% decrease in the average sales price of oil and a 69
MIDLAND, TX, June 26, 2023 (GLOBE NEWSWIRE) -- Mexco Energy Corporation (NYSE American: MXC) reported results on its Annual Report, Form 10-K to the Securities and Exchange Commission for the fiscal year ended March 31, 2023. The Company reported net income of $4,662,702 or $2.11 per diluted share, for fiscal year 2023, compared to net income of $2,855,066, or $1.32 per diluted share, for fiscal 2022, an increase of 63%. Operating revenues in fiscal 2023 were $9,557,289, an increase of 45% when
MGC Pharmaceuticals Ltd. (LSE: MXC), (ASX: MXC), (OTC: MGCLF), a leading European pharmaceutical firm specializing in plant-derived medications, announced today that its ground-breaking Investigational Medicinal Product (IMP), CannEpil®, has been successfully imported and received by its first patients in the United Kingdom.
MGC Pharmaceuticals Ltd. (LSE: MXC), (ASX: MXC), (OTC: MGCLF), a European based pharmaceutical company specializing in the development and supply of affordable, ethically produced plant-inspired medicines, announces that its proprietary product CannEpil® is now available to patients in the UK by Named Patient Request.
MIDLAND, TX, April 10, 2023 (GLOBE NEWSWIRE) -- Mexco Energy Corporation (NYSE American: MXC) announced today that its Board of Directors declared a special cash dividend of $0.10 per common share. The special dividend is payable May 15, 2023 to the stockholders of record at the close of business on May 1, 2023. The Company’s Board of Directors also authorized the use of up to $1,000,000 to repurchase shares of the Company’s common stock, par value $0.50, for the treasury account. This authoriza
MGC Pharmaceuticals Ltd. (LSE: MXC), (ASX: MXC), (OTC: MGCLF), a European based bio-pharma company specializing in the development and supply of affordable, ethically produced plant-inspired medicines, announces that its innovative product ArtemiC™ has recently been listed as an over-the-counter (OTC) drug in the USA on the FDA National Drug Code (NDC) Database under the code 83278. Facilitated by the company's US-based supply and distribution partner, AMCPharma USA, LLC. (AMC), ArtemiC™ will be
MIDLAND, TX, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Mexco Energy Corporation (NYSE American: MXC) today reported net income of $1,211,716, or $0.55 per diluted share, for the Company’s second quarter of fiscal 2023 compared with $708,828, or $0.33 per diluted share for the second quarter of fiscal 2022. Operating revenues in the second quarter of fiscal 2023 were $2,324,792. Net income for the six months ending September 30, 2022 was $2,510,388, or $1.13 per diluted share, an increase of 127% compare